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A B S T R A C T
Immune system has critical roles in ﬁghting against several diseases like cancer. Cancer cells evolve several ways
to escape from the immune system to remain alive and trigger new phases of cancer progression. Regulatory T
cells are one of the key components in tumor immune tolerance and contribute to the evasion of cancer cells
from the immune system. Targeting regulatory T cells could provide new horizons in designing and development
of eﬀective therapeutic platforms for the treatment of various malignancies. Curcumin is the bioactive pigment
of turmeric and a well-known phytochemical with a wide range of pharmacological activities. A growing body of
evidence has demonstrated that curcumin aﬀects manifold molecular pathways that are implicated in tumor-
igenesis and cancer metastasis. In this regard, some studies have indicated that this phytochemical could target
regulatory T cells and convert them into T helper 1 cells, which possess anti-tumor eﬀects. On the contrary,
curcumin is able to increase the number of regulatory T cells in other conditions such as inﬂammatory bowel
disease. Herein, we describe the anti-cancer roles of curcumin via targeting regulatory T cells. Moreover, we
summarize the eﬀects of curcumin on regulatory T cell population in other diseases.
1. Introduction
Cancer is one of the main causes of death through entire world. This
disease aﬀects more than 8.2 million people annually [1]. Histopatho-
logically, cancers often classify into two categories including metastatic
and non-metastatic forms [2]. During metastasis, some cancer cells
migrate from primary tumors and gain cellular features which could
contribute to their dissemination and colonization in the near and/or
distant organs [3,4]. Due to several genetic and epigenetic changes
cancer cells are more resistant to apoptosis which could lead to pro-
gression at diﬀerent biological processes including metastasis, angio-
genesis, uncontrolled cell proliferation and immune system dysfunc-
tions and escape [5,6]. Many strategies have been designed to control
cancer evasion including surgery, hormonal therapy, chemotherapy,
radiation therapy and immunotherapy [7]. Immune response is in-
itiated by "elimination phase" in which a great number of tumor cells
are killed by immune response. The second phase is "equilibrium phase"
in which the pressure of the immune system forces selection of tumor
variants, which leads to "escape phase". Tumor cells can evade from
immune system and growth uncontrollably during this phase [8]. T
cells are very important cells within these processes. More than 10% of
all immune cell types which inﬁltrate into the tumor sites are T cells
[9]. T helper (Th) cells are one of the T cell subsets, which are recruited
into tumor sites. These cells which are also correlated with good
prognosis in some tumor types produce some inﬂammatory cytokines,
such as IFN- γ and TNF-α [10]. In multiple types of tumors, including
lung and colorectal cancers, some types of T cells including CD8+
CD45RO+ memory T cells are related to a good prognosis [11–13].
Regulatory T cells (Tregs), an immunosuppressive T cell subset, are also
found in tumor microenvironment (TME) [14]. They have been shown
to be largely correlated with a poor prognosis in several cancers in-
cluding ovarian, pancreatic and breast cancers [15]. These cells pro-
duce some suppressive cytokines including IL-10 and TGF-β, and
modulate immune responses through direct and/or indirect interactions
[16,17]. It has been shown that Tregs are most often increased in
several cancers. Tregs suppress a wide range of immune responses [18].
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Multiple lines of evidence have documented that these classes of im-
mune cells may contribute to the escape of tumor cells from the im-
mune system. This can lead to tumor progression and low eﬃcacy of
chemotherapy in several malignancies [19,20]. Hence, Tregs are con-
sidered as candidate therapeutic targets in many cancers.
High levels of polyphenols are found in plant species. Promising
biological eﬀects of polyphenols, including anti-oxidant, anti-microbial
and anti-cancer properties have led to extensive research on the bio-
medical applications of these phytochemicals. In this regard, unstudied
wild plant species have been commonly investigated for ﬁnding novel
resources of worthwhile phyto-chemicals and overcoming universal
health challenges such as cancers, Alzheimer's disease, and diabetes
mellitus. Authors mainly pay attention to the plants with widespread
application in folk medicine. Nonetheless, there are a lot of data of the
above species, and emphasis on the species from a similar genus, on
which there is little information, will be a fascinating choice because
there may be similarities between their compositions and bio-chemical
activities. For this reason, future researches might focus on designing
potential phyto-pharmaceuticals [21].
Up to now, diﬀerent phytochemicals, including ﬂavonoids, phy-
toalexins, phenolic compounds and curcumin have been utilized as
adjuvant in cancer treatment which is due to their less toxicity and side
eﬀects as well as their potential modulating roles in various biochem-
ical processes involved in carcinogenesis [22–24]. One of the most well
studied phytochemicals is curcumin which is derived from the root of
Curcuma longa L. commonly known as turmeric [7,25]. Curcumin, also
known as diferuloylmethane, is a symmetric molecule. The Interna-
tional Union of Pure and Applied Chemistry (IUPAC) name of curcumin
is (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-
dione. Curcumin has a molecular weight of 368.38 g/mole and its
chemical formula is C21H20O6. Moreover, at least three chemical enti-
ties are found in the structure of curcumin, including two aromatic ring
systems with O-methoxy phenolic groups that are joined by a seven-
carbon linker containing α,β-unsaturated β-diketone moiety [26].
This yellow-colored powder has been widely used in several systems
of traditional medicine owing to its various beneﬁcial features in-
cluding anti-oxidant, anti-inﬂammatory, analgesic and antiseptic ac-
tivity [27–29]. Curcumin has been used to treat a wide range of in-
ﬂammatory and autoimmune diseases including arthritis, colitis and
hepatitis [28]. In recent years, anti-cancer features of curcumin has
been identiﬁed and it has been shown that this phytochemical and its
natural and synthetic analogues can aﬀect several biological pathways
and processes including mutagenesis, cell cycle, oncogene expression,
angiogenesis, metastasis and apoptosis [30–36]. Curcumin also mod-
ulates various physiological and pathological processes involved in
tumor cell growth, such as cell proliferation, cell survival, cell death,
tumor suppressor pathways, death receptor pathway, mitochondrial
pathways and protein kinase pathway [37–39]. Recently, it has been
suggested that anti-cancer properties of curcumin is not only due to its
eﬀect on various signaling pathways but also its immune modulating
eﬀects that enhance the immune system. This may lead to the elim-
ination of tumor cells even at early stages of tumorigenesis and in-
hibition of devastating tumor growth [23]. Thus, the purpose of this
review was to outline and discuss the role of curcumin in modulating
Treg cells functions in a cancer immunotherapy context.
2. T cells and cancer
For a long time, researchers have investigated the existence of T
cells in tumor biopsy samples and the respective possible eﬀects on
prognosis [40]. Initial information indicated that an inﬁltrate of T cell
in primary melanoma lesion has a prognostic role [41,42]. The same
ﬁndings have been obtained for other cancers such as ovarian cancer,
bladder cancer, renal cell carcinoma (RCC) and numerous solid cancers
[43–45]. However, the eﬀects of T cells inﬁltrations on clinical out-
comes is an open question. The positive impact of the existence of CD3,
CD8, and higher CD8/FoxP3 ratio has been found in one of the new
meta-analyses that examined clinical importance of tumor inﬁltrating
lymphocytes (TIL) in solid tumors (CD3, CD4, CD8, FoxP3, & ratios
between them) [46]. TIL density and distribution have been also eval-
uated, which revealed independent prediction of sentinel lymph node
conditions and survivals in the patients suﬀered from melanoma [47].
However, sub-types of T cells have been studied in details. For example,
Fridman et al. demonstrated the positive prognostic eﬀect of CD8/
CD45RO and Th1 T cell in most researches [11]. Therefore, there is a
relationship between memory T cells and/ or T cells with a Th1-biased
phenotype with a more favourable prognosis. Hence, Galon et al. ex-
amined nearly 400 patients specimens, and indicated CD8, CD45RO T
cells in the tumor core outperformed common clinical stages in color-
ectal cancers in terms of prognosis of the disease [48]. It should be
noted that even patients with localized disease exhibited very weak
prognosis that resembled to the prognosis of the patients suﬀered from
concomitant distant metastasis when their tumor had lower frequencies
of T cell in the core of tumor. Therefore, the overall rate of survival in
the patients will be largely determined by the local adaptive- and ap-
parently tumor-speciﬁc immune responses. It is clear that the above
situation emphasizes the crucial role of quantities and qualities of the
involved T cells and signiﬁcance of CD45RO T cells. In addition, T cells
ability for deep inﬁltration into the tumor core is necessary for their
antitumor activities [11].
Even though several researches indicated positive prognostic eﬀects
of TIL, the results need to be conﬁrmed in larger multifaceted clinical
studies in the future [49]. If we assume that ﬁndings of this research
approved eﬀects of immune inﬁltrate cells in colorectal cancer lesions,
prognostic devices would be fully modiﬁed with more advantages for
patients. Hence, chemotherapy treated a signiﬁcant fraction of patients
with local spread of disease. Nevertheless, the existing documents in-
dicate that a majority of the patients will have a lower risk of relapse if
the tumor has a considerable inﬁltration of memory T cells in the core
of tumor.
2.1. Regulatory T cells and various signaling pathways in cancer
Cancers are referred to as abnormal cell growth in an organ. The
ability of cancer cell dissemination to other organs of the body is one of
the major properties of many cancers. A variety of factors associated
with the pathophysiology of cancers have been identiﬁed [50]. De-
regulation of these factors ultimately leads to inﬂammation, apoptosis
resistance, angiogenesis, metastasis and immune system impairment
(Fig. 1). Among these processes, immune system in the TME plays a
critical role in cancer progression. TME is an important component of
cancer which is composed of diﬀerent non-immune and immune cells
including T cells [9]. T cells have pivotal roles in immune pathways and
immune responses [51]. At the early stages of carcinogenesis, naïve T
cells activate and migrate into the TME and eliminate immunogenic
cancer cells [52]. CD8+ T cells are the main anti-tumor cells which
diﬀerentiate into cytotoxic T lymphocytes (CTLs) [53]. CD4+ T helper1
(Th-1) can boost T-cell activation, CTL cytotoxicity, and promote anti-
tumoral activity of macrophages and NK cells via production of various
pro-inﬂammatory cytokines [54,55]. One of these cytokines is TNF-α
that is also produced by CTLs. This molecule has both pro- and anti-
tumor properties [56]. TNF-α can inhibit the activity of CTLs and an-
giogenesis in cancers [57]. However, this cytokine can inhibit the in-
ﬁltration of CD8+ T cells to the tumor areas. It has been reported that
TNF-α exerts its immunosuppressive eﬀects via alteration of the TME.
TNF-α can also induce TGF-β release to the TME and therefore induce
apoptosis in tumor cells [58,59]. TGF-β is another multitasking cyto-
kine which has a potential role in cancer progression [58]. This cyto-
kine has immunosuppressive properties and can increase the resistance
of tumor cells to immunotherapy [60,61]. In this way, TGF-β inhibits
the activity CTLs and NK cells. MMPs are pivotal enzymes for the de-
velopment of tumorigenesis and are involved in ECM degradation [62].
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Despite these carcinogenic features of TNF-α, this cytokine stimulates
immunoactivation against tumor cells (Fig. 2).
Another important factor in the signaling pathways of anti-tumor
activities of T cells is IFN-γ which is also a pro-inﬂammatory cytokine.
This cytokine is released from CTLs and Th1 cells and supports further
diﬀerentiation of CTLs to eﬀector CTLs [19,63]. IFN-γ inhibits angio-
genesis in tumor cells and promotes adaptive immunity [64]. This
molecule stimulates the diﬀerentiation of T cells into Th1 cells which
induces CTLs’ diﬀerentiation [64]. On the other hand, tumor cells can
decrease the release of INF-γ from T cells and therefore induce T cell
exhaustion by producing several immune escape mediators, such as PD-
L1, STAT3 and IDO1 [65,66]. IFN-γ induces the anti-metastatic activ-
ities of IL-12. CD4+ T cells and NK cells function and proliferation are
stimulated by IL-12 [67]. Besides pro-tumoric properties of IL-12, and
IL-6, these cytokines have inhibitory roles on CTLs and stimulatory
roles on Tregs activation [68,69].
Several studies have suggested that tumor cells can aﬀect anti-tumor
T cells via reducing T cells functions including their inﬁltration into the
tumors, their proliferation and survival, and their cytotoxicity [70].
Along these eﬀects, the surviving tumor cells create an immune-re-
sistance phenotype. Immune checkpoints on CTLs and CD4+ T cells (i.e.
CRLA-4 and PD-1) are other important factors which act as negative
regulators in anti-tumor response of T-cells. These checkpoints could
impact on the related anti-tumor activities of T cells (e.g. their migra-
tion, proliferation, and production of cytotoxic factors) [71,72].
Treg cells are another cell type that are found in TME. These cells
can control the protective immunity in cancers [73]. Cancer cells can
inhibit immune system by Treg cells [74]. These cells can inhibit
Fig. 1. Several signaling pathways involved in tumor (a) and anti-tumor immune response (b).
Fig. 2. Several underlying molecular mechanisms in cancer progression which aﬀected by regulatory T cells.
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multiple parts of the immune system responses including CD4+ and
CD8+T cells, B cells, DCs, monocytes, macrophages and NK cells [75].
Moreover, Treg cells can inhibit generation of eﬀector immune cells and
produce several immunosuppressant molecules, such as ROS, IL-1,
transforming growth factor (TGF)-β, vascular endothelial growth fac-
tors, prostaglandin E2, adenosine and galectin-1 [76,77], and also in-
hibit antibody production and co-stimulatory molecule expression. Treg
cells contribute to tryptophan catabolism and stimulate cytotoxic ac-
tivities on target cells by granzymes and perforin. In addition, Treg cells
can produce adenosine which is involved in several cellular activities,
such as immune suppression and modulation of vascular proliferation
[75]. Macrophages are one of the important immune system cells that
recruit 50% of cells into the TME [78]. Treg cells release several
mediators (i.e. IL-10, STAT3 and VEGF). These factors are able to pro-
mote the diﬀerentiation of monocytes into the M2 phenotype of mac-
rophage which have immunosuppressive properties [57]. M2 cells can
also activate Tregs by releasing IL-6 and IL-10 [79]. Tregs can activate
STAT3 signaling which induces immunosuppression by induction of M2
cells and promotion of cancer cell survival and tumor angiogenesis
[63,80,81]. Protein kinase B (AKT) is another target which is activated
in Treg cells and impacts on mammalian target of rapamycin complex 1
(MTORC1) [82]. MTORC1 induces hypoxia-inducible factor-1α (HIF-α)
that stimulates epithelial-mesenchymal transition (EMT) and cancer
cell promotion [83]. HIF1α along with STAT3 have binding sites for
VEGF which can enhance angiogenesis [84]. Thus, Treg cells can in-
ﬂuence all parts of immune response and could be suggested as a good
target for cancer immunotherapy.
3. Cancer immuno-therapy
Today, novel grounds of cancer immunotherapies have been pro-
vided by current approaches with the aim of the blockage of immune
checkpoint modulators, elimination of immune tolerance, including the
engineered T cells therapies, and determination of new tumor anti-gens
via the next-generation sequencing [85]. Cancer immunotherapy in-
volves passive or active immuno-therapy [86]. The former entails ad-
ministration of agents including mAbs, cytokines or lymphocytes,
which increase anti-tumor responses, and the latter tries to activate self
immune system for attacking tumor cells through vaccination, non-
speciﬁc immunomodulation, or targeting certain antigen receptors
[87].
3.1. Monoclonal antibodies
The Food and Drug Administration has given approval to more than
a dozen mAbs to treat solid and hematological malignancies. Moreover,
researchers currently examined more novel mAbs in clinical trials [88].
Additional uses of the present basic information of recognizing antigen,
activating T cells, and co-simulating T cells have been increased by
mAbs and gene transfer technologies. This condition resulted in in-
venting and succeeding checkpoint blockage and CAR T cells treatment
[89]. At present, numerous types of mAbs such as conjugated, bipeciﬁc
and naked mAbs are applied to treat cancers [90]. Conjugated mAbs
can be linked to a chemotherapy agent or a radio-active particle, which
takes one of these materials immediately to the cancer cell [91]. The
most common form of mAbs is naked mAbs that is used to treat cancer.
It may act by strengthening the immune responses versus cancer cells
and work as a marker for the immune system, which destroys them.
Chemo-labeled antibodies are those antibodies with powerful che-
motherapy attached to them, including brentuximab vedotin, which is
an antibody targeting CD30 antigen that exist on lymphocytes, attached
to a chemotherapy medicine, used for the treatment of Hodgkin lym-
phoma and anaplastic large cell lymphoma [92,93]. Radio-labeled an-
tibody has radio-active particles connected to them [94]. Bispeciﬁc
mAbs consist of parts of two various mAbs similar to the blinatumomab
boond to CD3 and CD19 that are applied for treating acute lymphocytic
leukemia (ALL) [95]. Low blood pressure, headache, fever, nausea,
chill, weakness and diarrhea are probable side eﬀects of mAbs [96].
3.2. Cancer vaccine
Cancer vaccine is the response modiﬁer, which acts via stimulation
or re-establishment of the immune system capability to ﬁght cancers
[97]. This vaccine contains preventative and treatment vaccines [98].
Preventive vaccines work on the basis of antigens taken by infectious
factors so that immune system can easily detect them as foreign at-
tackers [99]. The Food and Drug Administration approved hepatitis B
virus (HBV) vaccine and human papilloma virus (HPV) vaccine [100].
The vaccine triggers immune system with tumor antigen, peptide, or
the entire cancer cells [101]. It acts by activation of the immune system
with the targeted T cells for eradicating target cancer cells. Therapeutic
vaccines initially target the immune system directly and enlarge the
immune system's attack on cancer cells. Moreover, development of the
immune responses may be found because it can invade other tumor-
speciﬁc antigens (antigen spread) [102].
3.3. Adoptive T cell therapy (ACT) and T cells engineering
One of the most important forms of immuno-therapy for hemato-
logical malignancies and solid tumors is ACT of tumor-associated an-
tigen-speciﬁc T cells [103]. Previous researches on the ACTs, which
used tumor-inﬁltrating lymphocytes (TILs), are partially followed by
favorable clinical outcomes in metastatic melanoma patients [104].
However, such a strategy has been restricted due to the problems for
expansion of viable TILs and only exhibition of certain eﬀector func-
tions [105]. Therefore, for resolving the above problems, the ap-
proaches based on chimeric antigen receptor (CAR) and T-cells receptor
(TCR)-engineered T cells have been designed that act via modifying
genetic and increasing eﬃciency in diﬀerent clinical trials for speciﬁc
cancers [106].
Commonly, two key sources of T cell for ACT are the tumor itself
and peripheral blood of the patient with cancer [103]. One of the
substitute approaches is to transfer antigen-speciﬁc TCR gene into
lymphocyte, which has been separated from the peripheral blood of the
patient [107]. This could be done by transducing T cells with retro-
viruses or lentiviruses. Therefore, they may express TCRs, which target
certain cancer antigens and eliminate the cancer cells [107]. Even
though researchers obtained hopeful ﬁndings in metastatic melanoma
patients, TCR technology seemingly has been less attracted, since it is
MHC-restricted that restricts its additional development [108]. CAR-
modiﬁed T cells are the second category of the engineered T cells [109].
In comparison with TCRs, CARs possess antibody-like speciﬁcations
that may detect major histocompatibility complex (MHC)-non-re-
stricted structures on the target cells surfaces, and result in the re-
cognition of cancer cells in a MHC-un-restricted mode [110].
3.4. Immune checkpoint blockade (ICB) therapy
Immune checkpoint suppressors are a category of medicines de-
veloped with the aim of increasing immune responses versus cancer
cells [111]. The immune system contains diﬀerent checkpoints that
concentrate on activating T cells, which contribute signiﬁcantly to the
modulation of antitumor immunity. T cell surface molecules CTLA-4,
PD-1, T-cell immuno-globulin and mucin domain with protein 3 (Tim-
3), and lymphocyte activation gene-3 (LAG-3) are the molecules which
have an essential contribution to checkpoint modulation [101]. Tumor
expression of such markers would lead to hypo-responsiveness or even
exhaustion of immune system (113). Thus, the above molecules would
be strongly attended by researchers as the target to enhance cytotoxic T
cells for attacking and destroying cancer cells [112]. Today, more than
100 clinical trials are undergoing for testing eﬃciency and safety of
immune checkpoint blockade in diﬀerent types of cancers [111].
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Moreover, there is a relationship between checkpoint inhibition and
speciﬁc consequences such as hepatic, gastro-intestinal, endocrine,
dermatologic, and other less prevalent inﬂammatory episodes. As a
result, we need interrupting checkpoint suppressors and using corti-
costeroids in order to treat mild or severe consequences [113].
4. Curcumin and T cells
In experimental autoimmune myasthenia gravis, curcumin de-
creased the expression of T cell co-stimulatory molecules including
CD80 and CD86 and MHC class II as well as some inﬂammatory cyto-
kines including IL-17, INF-γ and TNF-α. Curcumin also increased the
levels of the anti-inﬂammatory cytokines, such as IL-10 [114]. It has
been shown that treatment with low-dose curcumin in a mouse model
decreased tumor growth and enhanced survival by increasing T cells,
especially proliferation and cytotoxicity of CD8+ T cells. It was con-
cluded that increased IFN- γ secretion could be a beneﬁcial eﬀect of
curcumin in anticancer therapy in lung cancer patients [115]. In T-cell
acute lymphoblastic leukemia malignant cells, curcumin treatment in-
duced inactivation of PI3 kinase targets including AKT, FOXO tran-
scription factor and GSK3 as well as cytochrome c secretion, and sub-
sequent caspase-3 activation and PARP degradation. Curcumin also
decreased the expression of inhibitor of apoptosis proteins (IAPs),
suggesting that curcumin treatment leads to the inhibition of pro-
liferation via induction of apoptosis [116]. An in vivo study investigated
the eﬀect of curcumin on resident intestinal immune eﬀector cells in
colorectal cancer. The results demonstrated that mucosal CD4+ T and B
cells were elevated by curcumin, suggesting that curcumin may reg-
ulate immune function via aﬀecting lymphocytes [117]. Application of
crude turmeric paste on skin tumors in rats showed that curcumin up-
regulated the expression of pro-apoptotic genes, such as caspase-2, 3, 8
and 9 as well as PARP and p53, while it down-regulated NF-kB and
VEGF in tumor tissues. A signiﬁcant reduction of CD4+, CD8+ and NK
cells was also observed following crude turmeric paste treatment [118].
Shao et al. examined the eﬀect of bisdemethoxycurcumin, a natural
derivative of curcumin, in combination with α–PD-L1 antibody on T
cell response against bladder cancer. They observed that bisde-
methoxycurcumin stimulated CD8+ T cell inﬁltration into tumor cells
and the level of IFN-γ while reducing the amount of myeloid-derived
suppressor cells [119]. Chandra et al. assessed the eﬀects of combina-
tion therapy with cryoablation - which kills tumor cells via freezing and
melting - and curcumin-phosphatidylcholine complex in a mouse model
of metastatic breast cancer. Both agents could increase T cells; for
curcumin due to the reduction of IL-6 in the TME. The results showed
that cryoblation in combination with curcumin-phosphatidylcholine
complex could decrease metastasis in a more eﬃcient manner com-
pared with cryoblation alone [120]. It has been demonstrated that
curcumin can promote vaccine therapy. An in vivo investigation con-
ducted by Singh and colleagues revealed that the amount of metastases
as well as tumor weight in the mice received Listeriaat‐based vaccine
and curcumin was markedly lower than control subjects. Moreover,
curcumin led to a reduction of IL-6 and induction of IL-12 by myeloid-
derived suppressor cells and also enahnced CD4 and CD8 T cell re-
sponses [121]. Table 1 summarizes various studies exploring the eﬀects
of curcumin on T cells in diﬀerent cancers.
5. Curcumin and regulatory T cells
In recent years, immunomodulatory eﬀects of curcumin have been
extensively studied. Curcumin can modulate T cells, B cells, macro-
phages, neutrophils, NK cells, dendritic cells and production of cyto-
kines and chemokines [28,122,123]. In addition, recent studies have
shown curcumin exerts immunosuppressive eﬀects [119].
In a recent in vitro study on the eﬀect of curcumin on the suppressive
activity of CD4+CD25+ Treg cells was investigated. The results showed
that curcumin could inhibit the suppressive activity of Treg cells via Ta
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inhibition of cytokine secretion especially IL-2 production as well as
reduction of Foxp3 expression in Treg cells. The nuclear translocation
of p65 and c-Rel, which are both important for the expression of Foxp3
and CD25, were signiﬁcantly reduced in Treg cells [124]. Another study
evaluated the eﬀect of curcumin on immune suppression in tongue
squamous cell carcinoma. Curcumin treatment inhibited the expression
of PD-L1 and p-STAT3 both in vivo and in vitro. In addition, after
treatment with curcumin the CD8+ T cells increased and Treg cells
decreased which resulted in the enhancement of anti-tumor immune
response [125]. Zhao et al. [126] investigated the immuno-modulatory
role of curcumin in a mouse model of colitis. Curcumin decreased the
inﬂammatory injury of the colonic mucosa and increased the number of
CD4+CD25+Foxp3+ Treg cells. Curcumin could also elevate the se-
cretion of IL-2, TNF-α, IL-12 p40, IL-6, IL-17 and IL21 and decreased co-
stimulatory molecules including CD252 (OX40), CD54 (ICAM-1),
CD205, CD256 (RANK), TLR4, and CD254 (RANK L) of DCs in a mouse
colitis model. In another study, the eﬀects of Theracurmin, a curcumin
nanoparticle, was examined on experimental colitis in mice. The results
of this study showed that curcumin nanoparticles suppressed the acti-
vation of NF-kB as well as mucosal expression of several proin-
ﬂammatory chemokines and cytokines, such as TNF-α, IL-1β, CXCL1
and CXCL2 in colonic epithelial cells. Curcumin also reduced neutrophil
inﬁltration in the colonic mucosa. This study also reported that cur-
cumin nanoparticle induced CD4+Foxp3+ Tregs and CD103+CD8α−
DCs in inﬂamed colon [127].
In a clinical investigation, after treatment with curcumin in colon
cancer patients, the number of forkhead box protein (Foxp) 3 positive
Treg cells were signiﬁcantly decreased while the numer of Th1 cells was
markedly increased. Curcumin therapy inhibited the Foxp3 expression
and enhanced IFN-γ secretion in Treg cells, which resulted in the con-
version of Treg cells to Th1 cells [128]. Another study investigated the
eﬀect of curcumin on Treg cells in lung cancer patients. The results
showed that after treatment with curcumin for 2 weeks, the number of
peripheral Treg cells were markedly decreased while the peripheral Th1
cells were increased. This study showed that curcumin enhanced the
conversion of Treg cells to Th1 cells by suppressing the expression of
Foxp3 and inducing the expression of INF-γ [129]. In order to study the
immunomodulatory eﬀects of curcumin as an adjuvant in cancer
treatment, curcumin-polyethylen glycol (PEG) conjugate, an amphi-
philic curcumin based micelle, was used in combination with vaccine
therapy in advanced melanoma model. This combination represented a
synergic antitumor eﬀect and resulted in decreased levels of im-
munosuppressive factors, such as myeloid-derived suppressor cells and
Treg cells. Besides, IL-6 levels were redcued in TME and of pro-in-
ﬂammatory cytokines, including TNF-α and IFN-γ and CD8+ T cell
population were increased. This study suggested that curcumin-PEG is a
potential agent to promote immunotherapy for advanced melanoma
[130]. Based on these ﬁndings, curcumin has potential eﬀects in sup-
pressing the activity of Treg cells. Due to the signiﬁcant role of Treg
cells in cancer development, it may be possible to use curcumin as an
immunotherapy for cancers in future. Tables 2 and 3 summarize various
studies on the eﬀects of curcumin on Treg cells in cancerous and non-
cancerous conditions.
Tumor tolerance which is deﬁned as immune system unrespon-
siveness to tumors plays an important role in cancer progression. Tumor
cells exploit various strategies to escape from the immune surveillance
[131]. To reach this goal, tumor cells increase the population of reg-
ulatory cells, including the CD4+CD25+FoxP3+ Tregs [132]. Tregs
block the eﬀective antitumor activities of immune system by releasing
some suppressive cytokines, including transforming growth factor
(TGF)-β [133]. Moreover, it has been shown that anti-Treg therapies
are able to inhibit cancer progression [134]. The immune eﬀector cells,
such as CD4+T cells, CD8+T cells, natural killer T cells and natural
killer cells release antitumor mediators, including interferon (IFN)-γ,
granzyme B, perforin to induce tumor cell fate [135–137]. In certain
environments, anticancer property of mentioned cells might be Ta
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impaired by Tregs in patients with malignancies [133]. Therefore,
Tregs inhibition is a potential approach to break the tumor tolerance
[138].
According to the current evidence, Tregs can be converted to other
CD4+T cell subtypes. For instance, it has been reported that Tregs can
be converted to Th17 cells [139]. Also, it was established that Tregs can
be converted to Th2 cells [140]. Th2 cells can also be converted to
Tregs [141]. Lee and colleagues indicated that Tregs were converted to
Th1 cells. They showed that conditioned dendritic cells caused this
conversion [142]. FoxP3, a transcription factor encoded by X-chromo-
some, is necessary for the function as well as diﬀerentiation of Treg
cells [143]. Tumor-inﬁltrating FoxP3+ Treg cells have been correlated
with poor outcomes in subjects aﬀected by diﬀerent solid tumors [144].
Zhao et al. reported the blockade of the inhibitory features of Tregs
in mouse models of lung and colon cancers by curcumin [145].
Autophagy is a catabolic mechanism, which is over-activated in
malignant cells and over-expressed in stressful conditions. It is an es-
cape mechanism in tumor cells, which occurs frequently for survival
[146]. Nonetheless, it is not clear whether blocking or inducing au-
tophagy can enhance the success rate of chemotherapy-mediated anti-
tumor responses. Masuelli et al. examined antitumor eﬀects of cur-
cumin with or without the autophagy suppressor chloroquine on Her2/
neu-overexpressing murine mammary cancer cell lines (TUBO). Cell
death in TUBO cells was increased by combining curcumin and chlor-
oquine and a little in nude mice. Yet, deactivation of curcumin cyto-
toxic eﬀect in immunecompetent mice has been observed by chlor-
oquine, because the lack of tumor repression and lesser survival has
been seen in those mice compared to just the mice given treatment with
curcumin. A signiﬁcant recruitment of Foxp3 T cells has been found in
the mice treated with curcumin or chloroquine that increased releasing
vascular endothelial growth factor (VEGF) and angiogenesing in the
TME and declined T cytotoxic cells against mice which have been
treated only with curcumin. The essential role of autophagy for evoking
anticancer immune responses has been indicated. Moreover, suppres-
sion of autophagy via chloroquine decreased the responses through
inﬁltration of Treg cells inside tumor and inhibition of anticancer
function of curcumin. Furthermore, it is possible to enhance the eﬃcacy
of chemotherapy or radiotherapy via inducing autophagy rather than
suppression [147].
In addition, curcumin may reduce Treg inhibitory potency and stop
its enhancement in the tumor-bearing host. Therefore, curcumin can
possibly suppress tumor-induced dysfunctions of T cell-mediated im-
mune response. Studies on tumorigenesis completely demonstrated
losing eﬀector and memory T cells, skewing immune responses from
Type 1 toward Type 2, and lower generation of eﬀector T cells.
Curcumin contributes to the successful restriction of the loss of T cells,
extension of the frequencies of memory T cells and eﬀector memory T
cells, invalidation of the Type 2 immune shift, and improvement of the
tumor-induced inhibition of generating T cells in tumor-harboring
hosts. Additionally, when the mice were treated with curcumin, in-
hibitory function of Treg cells was prevented by downregulation of
gene expressions of TGF-β and IL-10 in cancer cells. Ultimately, eﬀector
T cells' ability for eradicating tumor cell was found to be increased by
curcumin [148].
In another study performed on 40 patients with colon cancer, the
number of forkhead box protein (Foxp) 3 positive Treg cells were sig-
niﬁcantly decreased after the curcumin therapy, while the amount of
Th1 cells were markedly increased. Thus, curcumin therapy inhibited
the FoxP3 expression and enhanced the IFN-γ secretion in Treg cells,
indicationg possible conversion of Treg cells to Th1 cells [128]. Zou and
colleagues recently conducted a clinical trial to prove the converting
role of curcumin. They enrolled thirty patients with non-small cell lung
cancer and they were treated with curcumin for 2 weeks. The results of
this 2-week trial revealed that, before the curcumin therapy, the
amount of CD4+ CD25+ FoxP3+ Tregs was greater, while Th1 cells
number was lower in patients with lung cancer, in comparison with
healthy individuals. After treatment with curcumin, Tregs number was
decreased, while Th1 cells number was augmented in peripheral blood.
Consequently, they showed that curcumin is able to convert Tregs to
Th1 cells in aﬀected patients by suppressing expression of FoxP3 and
inducing the expression of INF- γ [149].
Joshi et al. indicated that Tregs restrain anti-cancer eﬀects of T cells
in tumor-associated tertiary lymphoid structures [150]. Hanagiri and
colleagues showed high expression of FoxP3+ cells as a poor prognosis
factor in the regional lymph nodes of stage I non-small cell lung cancer
patients [151]. Another study conducted by Son and colleagues de-
monstrated that a combination of ionizing radiation and Treg depletion
could increase radiation-induced anticancer eﬀect and further amelio-
rate outcomes of radiotherapy [152].
6. Curcumin as an adjuvant therapy in cancer
We need to understand properly the particular mechanism of the
parent medicine and combination approaches in order to provide a
reasonable design for achieving optimum eﬃciency [153]. Combina-
torial impacts with lesser, equivalent and or greater than the entire
impacts of distinct partner medicines may be obtained by combining 2
medicines. Combinatorial impacts might involve antagonistic, po-
tentiation, and synergistic [154]. If the achieved impact is greater
compared to the summed impact of the medicines without cross re-
activities and various acting targets or paths, we will observe sy-
nergistic combinatorial impact [155]. However, if the impact is higher
than or equivalent to the summed impact of distinctive medicines with
the resulting target as the same sites or pathways, we will have the
Table 3
Curcumin and regulatory T cells in cancer.
Disease Form of curcumin Target (s) Target gene (s) Doses/administration
route
Duration Model Ref
Melanoma cancer CUR-PEG+vaccine T-lymphocyte Increase
response
mice [130]
CD8(+) T-cell, IFN-γ, TNF- α Induction
Myeloid-derived suppressor
cells, Treg cells, IL-6
Inhibition
Lung cancer Curcumin CD4+ CD25+ Foxp3+ Tregs Inhibition 1.5 g/capsule, twice a
day
2 weeks Human (n= 30+6
healthy)
[149]
Th1 cells Induction Human
Fork head protein-3 Inhibition In vitro
Interferon-γ Induction In vitro
Tongue squamous cell
carcinoma
Curcumin PD-L1, p-STAT3 Inhibition In vivo and in vitro [125]
Treg cells Decreasing
CD8+ T cells Increasing
Advanced colon cancer Curcumin Foxp3 Inhibition 3 g 1 month Human (n= 40+30
healthy)
[128]
Th1 cells Induction
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additive impact. Regarding the potentiation impacts, we can see the
activity or impact of 1 medicine by the other. When the activities in-
creased, we will observe decreased consequences by regulating ADME
characteristics [156,157].
Curcumin has multi-faceted eﬀects in cancer therapy owing to its
numerous antineoplastic mechanisms. As a chemo-sensitizing agent,
curcumin may enhance the eﬃcacy of several chemotherapeutic agents
while reducing their dose and adverse eﬀects [154].
Chen et al. studied four anticancer chemo-therapeutic factors in-
cluding three tyrosine kinase suppressors (erlotinib, sorafenib and su-
nitinib), and doxorubicin, in combination with curcumin in vitro and in
vivo [158]. It was found that sunitinib combined with curcumin at a
molar ratio of 0.46 achieved the most potent synergistic eﬀect in vitro.
Thus, it has been selected to evaluate animals in detail [158].
Yue et al. examined antitumor eﬀects of curcumin or turmeric ex-
tract in combination with bevacizumab in HT29 colon tumor-bearing
mice [155]. Pharmacokinetic data demonstrated that the plasma levels
of curcumin of turmeric extract-fed mice had been maximized. This
indicates that turmeric extract possesses the most acceptable bioavail-
ability of curcumin. In addition, turmeric extract plus bevacizumab
therapy considerably suppressed tumor growth. These suppressive ef-
fects have been more inﬂuential compared to the eﬀects of cur-
cumin+ bevacizumab or bevacizumab individually, and could be
compared to the impacts of 5-ﬂuorouracil plus leucovorin plus ox-
aliplatin (FOLFOX) plus bevacizumab. It should be noted that no tan-
gible side eﬀects was caused by turmeric extract therapy, whereas
considerable side eﬀects were observed in FOLFOX-treated mice. Fi-
nally, combining turmeric extract with bevacizumab had potential an-
titumor eﬀects with no side eﬀect. This largely indicates the promise of
adjuvant application of turmeric extract for treating colorectal cancer,
particularly when combined with bevacizumab [155].
7. Limitations of curcumin
Although curcumin has been utilized as a safe, promising and po-
tential agent for chemoprevention and cancer treatment, it is not well
documented in the clinical setting. Curcumin has a low aqueous solu-
bility being about 11 ng/ml in water [159]. This feeble solubility causes
some diﬃculties in its oral administration. It is also hydrolyzed rapidly
and is degraded in alkaline and neutral media but has a higher solu-
bility in acidic condition. Furthermore, rapid systemic elimination and
metabolism are crucial factors leading to decreased systemic bioavail-
ability [160,161]. After intravenous or intraperitoneal administration,
an amounts of curcumin are excreted via bile in the form of hexahy-
drocurcumin and tetrahydrocurcumin glucuronide derivatives
[162,163]. The reduced bioavailability of oral curcumin in GI tract
restricts its potential eﬀects against cancer immunosuppression
[164,165]. The concentration of curcumin and its metabolites was
evaluated in peripheral and portal blood of patients with advanced
colorectal cancer receiving oral daily intake of 3600mg curcumin
[166]. The poor accessibility of curcumin after oral intake was re-
vealed, with nanomolar levels. Another investigation highlighted cur-
cumin limitations. In the mentioned study, cancer patients received
8000mg/day curcumin but only minute concentrations were measured
in the peripheral systems [167]. It has been found that, in subjects
received 10,000–12,000mg, increasing doses of curcumin from 500 to
8000mg was not measurable in patients' blood and only few levels of its
metabolites were detected [168,169]. Thus, development of an appro-
priate strategy to ameliorate the bioavailability and solubility of cur-
cumin is an essential issue for a beneﬁcial therapeutic approach against
immunosuppression induced by tumor.
8. Nanoformulations of curcumin: new insights into the future
Despite potential immunoregulatory eﬀects of curcumin, this phy-
tochemical has a low solubility in water, resulting in low oral
bioavailability [170,171]. To overcome the abovementioned limitation
for the bioavailability of curcumin, several nanotechnology-based drug
delivery systems have been developed. These systems are aimed at
targeting tumor cells, increasing biological functions and also enhan-
cing the solubility of curcumin. The drug delivery systems based on
nanotechnology have been demonstrated as beneﬁcial approaches to
eﬀectively transport insoluble drugs with improved bioavailability
[172]. To encapsulate curcumin successfully, numerous types of na-
noparticles are currently being employed, including micelles, nano-
particles, nanoemulsions, nanocrystals, liposomes, nanogels, suspen-
sions, phytosomes, inclusion complexes and dendrimers [173]. By
suppressing numerous markers of Treg cells and recover immune re-
sponses, these nanoparticles may limit tumor-mediated Tregs in ex-
perimental models [174].
Despite all the advantages of discussed delivery system, there are
certain limitations including drug targeting possibility, the capacity of
drug-loading, toxic eﬀects of the carrier materials or its metabolites,
fate of the carrier-molecule conjugates, production costs, large-scale
production and long-term stability. Particularly, the related toxic eﬀects
of nano-curcumin formulations are an essential parameter. Although
the carrier materials are examined for their biocompatibilities and
toxicities, the nanoparticle properties mostly diﬀer from bulk materials.
Therefore, before approval for use, detailed evaluations are required to
determine the toxicity of the carrier materials and their metabolites
[171].
9. Conclusion
Cancer is a leading cause of death worldwide. Despite many at-
tempts for ﬁnding new and powerful therapeutic approaches against
cancer, successful treatment is still challenged by many obstacles. One
of the major obstacles is escape of cancer cells from the host immune
system. Immune system and its components play very important roles
in eliminating tumor cells. Treg cells are one of the main components of
immune response which activate and/or inhibit several cellular and
molecular mechanisms contributing to the escape of tumor cells from
anti-tumor immune response. Hence, identiﬁcation of immune system
components is needed to ﬁght against cancer cells and also design or
develop novel immune system-based therapies. Tregs are therefore
considered as the most potent inhibitors of antitumor immunity and a
barrier against successful cancer immunotherapy. Modulation of Tregs
can improve the eﬀectiveness of cancer immunotherapy and has the
potential to induce tumor regression. Hence, it seems that identiﬁcation
of novel therapies that target Tregs could help improving the eﬃcacy of
anti-tumor immune responses against cancer cells. Among various
therapies, natural products have emerged as new therapeutic options in
the treatment of several disorders, such as cancer. Curcumin has dis-
tinct therapeutic activities including anti-oxidant, anti-inﬂammatory,
anti-microbial and anti-tumor properties. Curcumin has been shown to
aﬀect Treg cells in cancer models and is a candidate for adjuvant cancer
therapy. Pre-clinical experiments demonstrated the capacity of cur-
cumin in inhibiting Tregs activities via three major mechanisms i.e.
prevention of cell-to-cell interactions through downregulation of the
expression of immuno-suppressive molecules (i.e. CTLA-4), reduction of
suppressive cytokine secretion and reduction of IL-2 capability to be
consumed and/or stopping IL-2 production. In fact, curcumin con-
siderably reduced the expression of Foxp3 and nuclear trans-location of
p65 and c-Rel that are crucial for the transcription of Foxp3 and CD25
in Tregs.
Curcumin has a low solubility and a low oral bioavailability, which
have been proposed to attenuate its pharmacological activity in vitro.
Thus, it is reasonable to conceive possible improvement of the eﬀects of
curcumin on Treg cells and tumor growth using tailored delivery
systmes that enhance the bioavailability and biodistribution of this
phytochemical. It is suggested that further clinical trials are required to
show therapeutic properties of curcumin, particularly by using
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nanotechnology. Additionally, long-term evaluation of patients is ne-
cessary to prove the pivotal role of Treg in the pathophysiology of
cancer as well as the eﬀectiveness of curcumin in improving quality of
life of patients with cancer and enhancing the eﬀects of radio-
chemotherapy.
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